Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

• Published in: Clinical cancer research Vol. 25; no. 14; pp. 4530 - 4541
• Main Authors: Wu, Rui-Yan, Kong, Peng-Fei, Xia, Liang-Ping, Huang, Yun, Li, Zhi-Ling, Tang, Yun-Yun, Chen, Yu-Hong, Li, Xuan, Senthilkumar, Ravichandran, Zhang, Hai-Liang, Sun, Ting, Xu, Xue-Lian, Yu, Yan, Mai, Jia, Peng, Xiao-Dan, Yang, Dong, Zhou, Li-Huan, Feng, Gong-Kan, Deng, Rong, Zhu, Xiao-Feng
• Format: Journal Article
• Language: English
• Published: United States 15.07.2019

Immune checkpoint blockade (ICB) therapy induces durable tumor regressions in a minority of patients with cancer. In this study, we aimed to identify kinase inhibitors that were capable of increasing the antimelanoma immunity. Flow cytometry-based screening was performed to identify kinase inhibitor...